Park Avenue Compounding, St. Louis, MO
Is Park Avenue Compounding an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Park Avenue Compounding in St. Louis, MO, first registered Dec 23, 2023 and most recently registered Nov 3, 2026. FDA lists its last inspection as Sep 23, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Regulatory Meeting Held 5/7/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- St. Louis, MO
- Initial registration
- Dec 23, 2023
- Most recent registration
- Nov 3, 2026
- Last inspection
- Sep 23, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Regulatory Meeting Held 5/7/2026
- Intends to compound sterile drugs from bulk substances
- No
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Park Avenue Compounding, Saint Louis, MO, a 503B facility, with 1 listed action, including 1 Form 483 (2025).
| Document | |||
|---|---|---|---|
| Sep 23, 2025 | Amended Form 483 | Amended 483 Issued 09/23/2025 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Park Avenue Compounding, Saint Louis, MO (FEI number 1972829), matched to this page by exact name, city and state. It lists 5 inspections: 3 OAI, 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Feb 8, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 1972829 | 1231487 |
| Aug 28, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 1972829 | 1100607 |
| Nov 16, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 1972829 | 1033886 |
| Aug 14, 2014 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 1972829 | 892077 |
| Aug 5, 2009 | No Action Indicated (NAI) | Blood and Blood Products (Biologics) | 1972829 | 609213 |
Form 483s FDA has published for this site
- Sep 23, 2025: Form 483 to Park Avenue Compounding, published Dec 8, 2025. fda.gov
- Sep 8, 2024: Form 483 to Park Avenue Compounding, published Sep 16, 2024. fda.gov
- Sep 28, 2021: Form 483 to Park Avenue Compounding, published Jan 7, 2022. fda.gov
- Aug 28, 2019: Form 483 to Park Avenue Compounding, published Feb 24, 2020. fda.gov
- Oct 24, 2018: Form 483 to Park Avenue Compounding, published Jan 17, 2024. fda.gov
- Jul 23, 2015: Form 483 to Park Avenue Compounding, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 22 numbered observations in all, across 3 inspections ending Aug 28, 2019 to Feb 8, 2024. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 8, 2024: 10 observations
- Firm on the cover
- SSM Health Care St. Louis DBA SSM St. Clare Health Center, 1015 Bowles Ave, Fenton, MO 63026-2394
- FEI number
- 1972829
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 8050 Marshall Dr., Suite 205 Lenexa, KS 66214
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
A. You observed two potency failures for Morphine Sulfate 50 mg in 50 mL of NS (I mg/mL). OOS QAL-22-016, batch <Redacted B4> occurred on approximately 2/2/2022 with a result of 206.5% (2.1 mg/mL) and OOS QAL-22-059, batch <Redacted B4> occurred on approximately 11/10/2022 with a result of 76.0% (0.8 mg/mL). Your specification is <Redacted B4>. Each of these failures were considered confirmed product failures. While you implemented interim CAP A-22-003 <Redacted B4> was not effective until approximately 5/16/2022. During this period (02/2022 -5/2022) you made <Redacted B4> more batches of Morphine Sulfate 50 mg in 50 mL of NS (1 mg/mL). This new batch <Redacted B4> step was not documented during the manufacturing of these batches of Morphine Sulfate. ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A. The aseptic processing area is not adequately monitored during production. In addition, there is a lack of scientific rationale behind the selection process for the monitoring locations, and there is insufficient data to ascertain whether these chosen sites produce significant or meaningful results.
1. The active viable monitoring is only performed after production activities have ceased. In addition, the active viable air monitoring device is placed against the back wall of the right ISO 5 Laminar Flow Hood. This placement could bias the readings towards the conditions directly adjacent to the filter, providing an inaccmate representation of the overall air quality within the hood.
3. During production of lot 20240130-10515F on Januaiy 30, 2024, I observed the settle plate placed in the <Redacted B4> of the ISO 5 Laminar flow hood. It was located directly behind a spray bottle of <Redacted B4> used to spray surface area and production technician <Redacted B4> hands, forearms and chest throughout the compounding process. ...
Observation 3
The operations relating to the processing of penicillin are not peiformed in facilities separate from those used for other drug products for human use.
Specifically,
According to a trending report dated 1/1/2022-1/2/2023 503A penicillin and beta lactam products were consistently compounded inside the 503B hood <Redacted B4> during 2022 and for <Redacted B4> of 2023. During this timeframe, over <Redacted B4>instances of 503A compounding beta lactam product including but not limited to ampicillin and pemcillin in the same hood 503B compounding production activities are performed in were documented. Examples include but are not limited to:
PENICILLIN G POTASSIUM UP TO 3 MU IN 50 M~ <Redacted B4>
PENICILLIN G POTASSIUM UP TO 3 MU IN 50 ML <Redacted B4>
AMPICILLIN-SULBACTAM 1.5 G IN 50 ML <Redacted B4>
AMPICILLIN-SULBACTAM 1.5 G IN 50 ML <Redacted B4>
MEROPENEM 1000 MG IN 50 ML <Redacted B4>
MEROPENEM 1000 MG IN 50 ML <Redacted B4>
CEFAZOLIN lG POCKET FLUSH <Redacted B4>
ERTAPENEM 1000 MG IN 50 ML <Redacted B4> (USING <Redacted B4> VIAL <Redacted B4> l l
Observation 4
An adequate number of batches of each drug product are not tested to determine an appropriate expiration date.
Specifically,
You discontinued your stability program in 2022 per your site leadership personnel. You have continued to produce various drug products to include but not limited to approximately <Redacted B4> lots of Phenylephrine HCl 1000 mcg in 10 mL of NS (100 mcg/mL) in 10 mL in lot sizes approximating <Redacted B4> units.
Observation 5
Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically,
A. On Januaiy 30, 2024, I observed a stain on the HEPA filter located in the ISO 5 Laminar Flow Hood used during the compounding of lot I v<Redacted B4> Fentanyl 2mcg/mL and Ropivacaine 0.2% in 0.9% sodium chloride 150mL. Total uruts compounded were <Redacted B4> lS0mLbags.
B. While conducting cleaning procedures prior to the beginning of compounding on Tuesday Januaiy 30, 2024, it was observed that the production technician cleaned the computer tablet, the mount securing the tablet to the exterior of the right ISO 5 Laminar Flow Hood, and the wires situated outside the ISO 5 laminar flow hood. Subsequently, the same wipe was employed to clean the Repeater pump located inside the ISO 5 laininar flow hood.
Observation 6
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically, The following observations were noted while observing the aseptic compounding of <Redacted B4> 150mL units of lot <Redacted B4> Fentanyl 2mcg/mL and Ropivacaine 0.2% in 0.9% sodium chloricle 150mL:
V
B. Blocking first air while removing the cap which exposes the septum of the fentanyl vial as well as when removing the cap covering the injection port of the finished product IV bags.
C. <Redacted B4> the outer packaging of components instead of <Redacted B4> the packaging open while inside the ISO 5 Laminar flow hood.
Observation 7
Employees engaged in the manufacture and processing of a dmg product lack the training required to perfo1m their assigned functions.
Specifically,
A. The AQL visual inspection lacks scientific justification for acceptable limits on critical, major, and minor defect levels. Furhtermore, there is an absence of established in-process limits for critical and major defects during the visual inspection process.
B. Your visual inspection qualification <Redacted B4> and the master defect log are not access controlled. You allow visual inspectors who perform AQL inspections access to your qualification <Redacted B4> without restriction. These 4 lfare used to initially qualify and <Redacted B4> equalify all visual inspectors. In addition, all units in the certification, are numbered. Unlimited access to a single visual inspection with numbered units raises concerns about the potential for operators to memorize the <Redacted B4> which could compromise the accuracy of the visual inspection process.
C. You are not documenting the duration of operator qualification on inspection <Redacted B4>. ...
Observation 8
Written records of investigations into the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
Specifically,
A. You failed to initiate investigations regarding inadequate cleaning in the ISO 5 laminar flow hood. On January 30, 2024, an area of apparent rust was observed in the ISO 5 laminar flow hood. Your QA manager stated this was actually oxidized <Redacted B4> residue. When asked how she knew this, she reported we have seen it before. As of February 7, 2024, there is no record of an investigation initiated for this quality event.
B. There is no record of an investigation or a planned deviation when new equipment must be temporarily introduced into the ISO 5/7 area. For example, when compounding batch <Redacted B4> Phenylephrine HCI 1000 mcg in 10 mL of NS in 10 mL <Redacted B4> Syringe, a note stating: "There were issues with the normal cleanroom tablet connecting to the WiFi during the batch. The backup tablet was cleaned and used during part of the batch by the operator.". This planned deviation was not documented. ...
Observation 9
The labels of your outsourcing facility's drug products are deficient.
1. Specifically, the following information is not found on your labels:
a) The statement "This is a compounded drug";
b) The name, address and phone number of the outsourcing facility;
h) The following information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088
Examples of your labels that do not contain all or some of the required information specified above:
• Order <Redacted B4> ertapenem <Redacted B4> 1,000mg in 0.9% NaCl IV 50mL IVPB
• Order# <Redacted B4> ampicill
in-sulbactam <Redacted B4> 1.5g in 0.9% NaCl IV 50mL IVPB
t,Xt>ner.(bT(7)(C),(ti)T4l d' B' b 8 150mE • d 5°1'. • fu • • 0rder# <Redacted B4> for Sodium Bicarbonate 8.4% 150mEq in dextroae 5% infusion (fluid)
s
• Order # <Redacted B4> for Chlorpromazine <Redacted B4> 25mg in 0.9% NACl IV 50mL infusion
• Order#<Redacted B4> for <Redacted B4> infusion
• Order# <Redacted B4> Lidocaine <Redacted B4> 1.30mL, Epinephrine 1mg/1mL, sodium bicarbonate 8.4% 12.5mEq, tranexamic acid <Redacted B4> 1,000mg in 0.9% NaCl IV infiltration
b 4
• Fentanyl citrate 2500mcg/50mL IV
Observation 10
• Order# <Redacted B4> for Sodium Bicarbonate 8.4% 150mEq in dextrose 5% infusion (fluid)
• Order# <Redacted B4> for Chloropromazine <Redacted B4> 125mg in 0.9% NACl IV 50mL infusion
• Order# <Redacted B4> for <Redacted B4> infusion.
• Order# <Redacted B4> Lidocaine <Redacted B4> 1% 30mL, Eoinephrine lmg/lmL, sodium 1 bicarbonate 8.4% 12.5mEq, tranexamic acicl <Redacted B4> 1,000mg in 0.9% NaCl IV infiltration
Inspection Sep 16, 2021 to Sep 28, 2021: 4 observations
- Firm on the cover
- SSM Healt h Care St. Louis DBA SSM St. Clare Health Center, 1015 Bowles Ave, Fenton, MO 63026-2394
- FEI number
- 1972829
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 8050 Marshall Drive, Suite 205 Lenexa, KS 66214
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Written records of investigations into the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
Specifically,
A. On 09/17/2021, I observed visibly wet, apparently leaking, IV bags containing Potassium Chloride 40 mEq in 270 ml 0.9% Sodium Chloride for injection, lot <Redacted B4> . The IV bags were in a <Redacted B4> unit case, which had already passed 100% visual inspection. The 0.9% sodium chloride IV bags used to compound Potassium Chloride 40 mEq in 270 ml 0.9% Sodium Chloride for injection, lot <Redacted B4>, were from bag manufacturer lot <Redacted B4> then observed two wet puddles on the prep cart used to stage IV bags for the next batch of product, which had passed initial inspection when removing the outer bag from the IV bags. The 0.9% sodium chloride IV bags on the cart were also from bag manufacturer lot <Redacted B4>. Your Operations Pharmacist showed me a tray of approximately leaking bags of 0.9% sodium chloride, which he discovered and quarantined when staging the prep cart. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
Your visual inspection program is inadequate as evidenced by the following:
A. It lacks defined defect categories, such as critical, major, and minor. Your SOP OPS.007, Visual Product Check, effective 08/09/2021, mentions checking for critical, major, and minor defects during visual inspection qualification, but it does not define what types of defects fall under each category. In addition, your firm compounds sterile drugs in IV bags, syringes, and vials. You have no defined defect types specifical ly for IV bags, syringes, and vials.
addit ion, your firm compounds sterile drugs in IV bags, syringes, and vials. You have no defined defect types specifical ly for IV bags, syringes, and vials. B. You have no established threshold for defects found during visual inspection as it relates to the disposition of the batch.
C. Your visual inspection qualification kit is comprised of bags, vials, and syringes taken from production. The defects in the kit are coring particles in an IV bag. ...
Observation 3
Written procedures are lacking which describe in sufficient detail the receipt, identification, testing, approval and rejection of components, drug product containers and closures.
Specifica lly,
A. You stated you do not inspect critical components upon receipt, including, but not limited to, sterile 0.9% sodium chloride IV bags and sterile vials of bulk drug substances. You stated critical components are looked at while preparing for compounding operations, but there is no officially documented inspection step. In addition, you have not established any thresholds for rejecting a batch of critical components based on the number of defects found during routine inspections or downstream visual inspection operations.
B. You stated you do not perform identity testing on received sterile vials of drug products used in the compounding of sterile drug products. The received sterile drug products include, but are not limited to, <Redacted B4> and <Redacted B4>
compounding of sterile drug products. The received sterile drug products include, but are not limited to, [liJ(4l I and(DJ(4J I [b)(4]1
Observation 4
The labels of your outsourcing facility's drug products are deficient.
Specifically,
A. The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A). Specifically, the following information is not found on your drug product labels:
i. The dosage form and strength; Examples of your product labels that do not contain this information:
• Fentanyl citrate 2 mcg/ ml and ropivacaine HCI 0.2% in 0.9% Sodium Chloride 150ml
• Norepinephrine bitartrate 8 mg in dextrose 5% 250ml (0.032mg/ml)
• Dil tiazem HCI 125 mg in 0.9% Sodium Chloride 125 ml (lmg/ml)
• Potassium Chloride 40 mEq in 0.9% Sodium Chloride 270ml
• Oxytocin 30 units in 0.9% Sodium Chloride 500 ml (0.06 units/ml)
• Fentanyl citrate 10 mcg in 0.9% Sodium Chloride (10 mcg/ml) (1ml vial)
• Neostigmine methylsulfate 5 mg in 5 ml (1 mg/ml) (5 mls in 10ml syringe)
• Succinylcholine Chloride 100 mg in 5 ml (20 mg/ml)
B. The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(8). Specifically, the following information is not found on your drug product container labels:
i. ...
Inspection Aug 20, 2019 to Aug 28, 2019: 8 observations
- Firm on the cover
- SSM Health Care St. Louis DBA SSM St. Clare Health Center, 1015 Bowles Ave, Fenton, MO 63026-2394
- FEI number
- 1972829
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 8050 Marshall Drive, Suite 205 Lenexa, KS 66214
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
(A) Operators were observed contacting surfaces such as the handles to the <Redacted B4> doors in the ISO 7 non-hazardous clean room with gloved and ungloved hands. Operators also contacted surfaces in the ISO 7 anteroom with gloved and ungloved hands.
(B) Smoke studies performed in the ISO 5 hoods under dynamic conditions were not representative of normal production operations using the repeater pump and did not simulate the production of total parenteral nutrition (TPN). The smoke studies were conducted in empty hoods, and only basic manipulations were simulated.
(C) During production, the lid of the trash can was observed to be up blocking the path of air exiting of ISO 5 laminar airflow hood (Hood Left), which has the potential to create turbulent airflow within the ISO 5 hood.
(D) The firm has not conducted media fills simulating the TPN production process.
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
(A) The firm does not routinely perform viable and nonviable environmental sampling in classified rooms or hoods during the production of drug products prepared pursuant to patient-specific prescriptions. Additionally, the door handles of the cleanroom, the handles of the <Redacted B4> door, and the computer keyboards in the anteroom and <Redacted B4> room, which are frequently touched with gloved and ungloved hands during operations, are not included in the firm's environmental monitoring program without justification.
(C) Large <Redacted B4> between ISO 7 anteroom and unclassified area are not interlocked and both doors can be opened at the same time.
Observation 3
Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet appropriate statistical quality control criteria as a condition for their approval and release.
Specifically, your firm's product inspection process is deficient in that you do not always perform 100% visual checks against a contrasting background of your sterile drug preparations and repackaged drug products prior to release. For example, the following lots of product were released by your Quality Unit without 100% visual inspection:
Product Name Lot#
Exp. Date
Batch Size
# of Units Inspected
% Visually Inspected
Norepinephrine Bitartrate 8 mg in Dextrose 5% 250 ml
09/17/2019 <Redacted B4> <Redacted B4> {bf(il] 22%
• Oxytocin 30 Units in 0.9% Sodium Chloride 500 ml
bf{l 190626-015
09/24/2019 <Redacted B4> <Redacted B4> {6) <"] 25%
Phenylephrine HCI 1000 mcg in 0.9% Sodium Chloride 10 ml
bf{l b) (4} 190617-011
09/15/2019 <Redacted B4> <Redacted B4> 25%
Succinylcholine Chloride 100 mg in 5 ml Syringe
fif(,lj bJll 181022-013
01/20/2019 <Redacted B4> <Redacted B4> 20% ...
Observation 4
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Specifically, the batch release testing for drug products with large batch sizes are only tested for potency, sterility, and endotoxin. The firm does not routinely test for pH and subvisible particulates as part of batch release testing.
Observation 5
Written specifications for laboratory controls do not include a description of the sampling and testing procedures used.
Specifically,
(A) The firm does not have an established procedure on collection of personnel monitoring samples. On 8/20/ 2019, the pharmacist was observed swabbing different locations of the operator's gown using <Redacted B4> cotton swabs, and then streaking the samples on <Redacted B4> plates.
(B) The firm does not have an established procedure describing how culture media plates should be read. On 8/ 22/2019, the pharmacist reported no growth for a <Redacted B4> plates of personnel monitoring and environmental monitoring samples collected on 8/20/2019 during Oxytocin 30 Units in 0.9% Sodium Chloride 500 ml (Lot# 190820-010) production. However, one (1) colony was observed on the edge of the <Redacted B4> plate for the sample collected from the <Redacted B4> area of the operator's gown.
Observation 6
Adequate ventilation is not provided.
Specifically, there is no HEPA filter in the ceiling of the anteroom and non-hazardous buffer room. The air from the air handling unit (AH) <Redacted B4> travels through a remote HEPA filter located in the ceiling above an unclassified room and then travels along ductwork and enters the ISO 7 non-hazardous cleanroom and ISO 7 anterooms through air supply grills in the ceiling. There is inadequate control, maintenance, and assessment of the cleanliness of the ductwork leading from the remote HEPA filters to the air supplies located in the ceiling of the ISO 7 anteroom and ISO 7 non-hazardous cleanroom.
Observation 7
Employees are not given training in the particular operations they perform as part of their function, current good manufacturing practices and written procedures required by current good manufacturing practice regulations.
Specifically,
(A) The firm's aseptic gowning qualification program does not include assessment of the ability of the cleanroom operator to maintain the quality of the gown after performance of gowning procedures.
(B) The firm does not have a training program for the collection of personnel monitoring samples.
(C) The firm does not have a training program for reading culture media plates.
Observation 8
Clothing of personnel engaged in the manufacturing, processing, packing and holding of drug products is not appropriate for the duties they perform.
Specifically,
(A) Personnel were observed handling the sterile gown with ungloved hands and donning subsequent gowning components without hand sanitization.
(B) Sterile gowns are reused when operators prepare products pursuant to patient specific prescriptions.
Linked 483s whose text is not shown
- Sep 23, 2025: FDA document 190024: its numbered observations could not be read reliably from the PDF text.
- Sep 23, 2025: FDA document 190198: the PDF is a scanned image with no readable text.
- Oct 24, 2018: FDA document 109511: its numbered observations could not be read reliably from the PDF text.
- Jul 23, 2015: FDA document 89530: its numbered observations could not be read reliably from the PDF text.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Park Avenue Compounding). That is not a finding beyond this index’s search.
The Park Avenue Compounding pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.